Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12860010 | 0.86 | GAA (0.37) | KMT2AMEN1AURKAALDH1A1POLB | |
| SCHEMBL544943 | 0.85 | MEN1 (0.41) | KMT2ACYP2C19MEN1MCOLN3LMNA | |
| SCHEMBL544674 | 0.85 | SMN1; SMN2 (0.52) | KMT2ACYP2C19MEN1MAPTAURKA | |
| SCHEMBL545135 | 0.83 | CYP2C19 (0.43) | KMT2ACYP2C19MEN1ALDH1A1LMNA | |
| SCHEMBL2797226 | 0.82 | MAPT (0.40) | KMT2ACYP2C19MEN1MAPTAURKA | |
| SCHEMBL10083061 | 0.80 | PPARG (0.43) | AURKAALDH1A1MAPK1GAASMN1; SMN2 | |
| SCHEMBL5961926 | 0.74 | MAPT (0.55) | KMT2ACYP2C19MEN1MAPTPOLB | |
| SCHEMBL9989762 | 0.74 | MAPT (0.55) | KMT2ACYP2C19MEN1MAPTPOLB | |
| SCHEMBL544652 | 0.73 | GAA (0.43) | ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL15777831 | 0.73 | KMT2A (0.47) | KMT2AMEN1MAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110699-B2 | Cobalt-catalyzed asymmetric cyclopropanation of alkenes with α-nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110699-B2 | Cobalt-catalyzed asymmetric cyclopropanation of alkenes with α-nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110699-B2 | Cobalt-catalyzed asymmetric cyclopropanation of alkenes with α-nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081838-A1 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates | PPOX, IDH3A, HMOX2 | KMT2A 1179/4885CYP2C19 839/4885MEN1 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.